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This report summarizes the progress and
applications of the baculovirus expression
vector system (BEVS) in insects. An
International Baculovirus and Insect Cell
Gene Expression Conference was held
26-30 March 1995 in Pinehurst, North
Carolina, to share and disseminate research
in this emerging field of biotechnology.
More than 200 people from 22 countries
participated in the conference, which was
sponsored by American Cyanamid, Glaxo
Inc. Research Institute, and 9 other
biotechnology companies. The conference
consisted offour sessions: baculovirus biol-
ogy, expression technology, host systems,
and applications. Each session began with
a historical review ofthe topic, followed by
a series oflectures by invited speakers and
short presentations by selected conference
participants, with poster presentations in
topical areas. Research presented focused
on the applications in environmental,
human, and animal health, and the
prospective uses of baculovirus technology
to produce safe biopesticides as replace-
ments for chemical insecticides for crop
protection or to design and synthesize
recombinant biopharmaceutical products
for the treatment ofhuman disease.
The baculovirus expression vector is a
helper-independent, eukaryotic DNA viral
vector that infects lepidopteran (butterflies
and moths) insects and insect cells.
Approximately 500 recombinant genes have
been expressed in the BEVS under the tran-
scriptional regulation of single or multiple
baculovirus promoters representing genes of
immediate early, delayed early, late, and
very late promoter classes, the most com-
mon being the polyhedrin promoter. An
advantage ofBEVS over bacterial expression
systems is that BEVS expressed proteins are
often post-translationally modified similar
to mammalian cells, which is an important
factor for biological activity and protein
function studies. Ninety-five percent of
expressed recombinant proteins are biologi-
cally active. The prototype baculovirus is
the Autographa californica nuclear polyhe-
drosis virus (AcNPV). The three most pop-
ular insect cell lines used in the BEVS are
Sf9 and Sf21 from the fall armyworm,
Spodopterafrugiperd, and TN5B1-4 (High
5) from the cabbage looper, Trichoplusia ni.
High 5 cells typically exhibit greater recom-
binant protein synthesis than Sf9 or Sf21.
However, the high metabolic activity ofthis
cell line results in a higher proportion ofby-
product accumulaton.
In the natural environment, when
infected lepidopteran larvae (caterpillars)
die, polyhedrin encapsulated baculovirus
particles left in the decomposing tissue
contaminate adjacent plants. Uninfected
larvae feed on the contaminated plants,
ingest the polyhedra, and become infected.
Infection begins in the midgut, where the
polyhedrin protein dissolves in the alkaline
environment and progresses through the
larvae via the tracheal system. Recent stud-
ies have revealed that baculovirus DNA
replication triggers apoptosis, the host's
primary defense, which results in an
abortive infection at both the cellular and
organismal level. The ability to block cellu-
lar apoptosis would greatly increase the
infectivity and host range of the bac-
ulovirus and increase recombinant protein
production and stability. The AcNPV
encodes two genes to accomplish this: p35
and iap. The human proto-oncogene bcl-2
also inhibited insect cell apoptosis when
co-expressed with recombinant protein.
Plant andAgricultural Research
The BEVS has tremendous potential in agri-
culture as an environmentally safe biopesti-
cide against lepidopterans, which cause mas-
sive amounts of damage to crops and orn-
mental vegetation. Several recombinant pro-
teins were reported at this meeting to have
been successfully expressed in whole insects
using baculovirus vectors, to study insect
metabolism, improve post-translational
modification and localization, and to synthe-
size large quantities ofthe recombinant pro-
tein. The success of these studies indicates
that the baculovirus could be safely dispersed
on crop surfaces and produce a fatal infec-
tion after ingestion by lepidopteran larvae in
agricultural crop fields. There were several
presentations at this conference by scientists
engaged in agrichemical BEVS research
describing progress toward a marketable
biopesticide. The parameters to consider in
evaluating new pesticides include efficacy,
host range oftheproduct, environmental sta-
bility, production, formulation, cost, and
marketing. The AcNPV infects only lepi-
dopterans; it is completely harmless to all
vertebrates and other invertebrates. The
wild-type virus alone has a deleterious effect
on the host insects and can reduce crop
destruction to some degree. Feeding by the
infected host is inhibited onlyduring the ter-
minal stages ofinfection. Removing the viral
genes that act to promote feeding activity
and prolong the life of the insect would
improve the efficacy of the wild-type virus
by killing the host faster. The AcNPV EGT
gene is an example of this class of genes.
Field trials are in progress using an EGT-
deleted (EGTDEL) construct. Insertion ofa
species-specific, lethal gene into the virus
genome increases both the efficacy and the
specificity of the system. The recombinant
virus is sprayed on the crop and subsequent-
ly ingested by the larvae. As the virus repli-
cates and the infection progresses in the host,
the deleterious, recombinant protein is syn-
thesized and metabolized by the insect. The
baculovirus becomes a delivery system for
the toxic gene, which kills the host more
quickly than the wild-type virus. The most
commonly studied recombinant toxic gene
product is AaIT, a 70-amino acid insect-
selective, scorpion protein that induces con-
tractile paralysis in the prey by binding to
the voltage site on sodium channels. When
cloned in AcNPV, AaIT showed a 38%
improvement in speed of action compared
to the wild-type strain and gave significantly
enhanced control oflarval feeding damage in
whole plant studies. In in vitro experiments,
an EGT-deleted-AaIT inserted construct
(vEGTDEL-AaIT) was the most effective
biopesticide against lepidopteran cells. Field
tests using vEGTDEL-AaIT AcNPV have
been proposed and are pending EPA review.
Although the wild-type AcNPV is registered
with the EPA, baculovirus biopesticides face
many barriers before they could be success-
fully marketed. The wild-type virus is less
effective than pyrethrin and more expensive,
diminishing the economic incentive for use.
Each recombinant construct must undergo
government-approved field testing before
receiving EPA registration. To be competi-
titve in the future pesticide market, the bac-
ulovirus biopesticides must be as economical
as chemical insecticides, and public safety
concerns about genetically engineered prod-
ucts must be addressed.
Biomolecular Research
The BEVS is a powerful tool for produc-
tion of large quantities of recombinant
mammalian protein for biomolecular
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research. The biological activity and simi-
larity to native proteins offer great advan-
tage over conventional bacterial expression
systems. Secretion signal peptides, nuclear
localization signals, chaperone proteins, and
catalytic folding proteins, missing in the
BEVS, can be cloned into the viral genome
and co-expressed with the desired recombi-
nant protein, permitting proper folding,
transport, and localization. The post-trans-
lational modification which received the
greatest attention at this conference was
glycosylation. In insect cells, glycosylation,
especially processes that result in complex
N-linked side chains containing outer chain
galactose and/or terminal sialic acid, often
produces oligosaccharide sequences that are
not identical to those in the respective
native proteins. The theory presented was
that following induction of the glycosyl-
transferase enzymes during infection, glyco-
sylation processes switch from the high
mannose-type glycan assembly normal for
lepidopteran cells to a complex type of
oligosaccharide processing. The transition
results in a hybrid process and infidelity.
Many human proteins have been expressed
using the BEVS for basic research, com-
mercial applications, and development of
new pharmaceuticals.
Development of stably transformed
insect cell lines, in which heterologous
genes are integrated into the insect cell
genome, offers several advantages over con-
ventional BEVS infection and represents
the newest extension of insect cell gene
expression technology. The cell lines
described at this conference do not experi-
ence cell death and lysis associated with
viral replication, and they utilize the nor-
mal host cell secretary pathways, demon-
strate improved secretion and organelle tar-
geting of the recombinant protein, and
facilitate the production of expression
libraries. Stable expression offoreign genes
in Sf9, Drosophila S2, and Aedes albopictus
cells has been accomplished, but the recom-
binant proteins are currently expressed at a
lower level than in the BEVS.
Medical Research
The ultimate test of medical research is
whether the compound studied or the
product developed can be implemented in
a clinical setting to benefit the human pop-
ulation. As part of the transition from
research laboratory to clinical trial, the
drug or chemical must receive approval
from the Food and Drug Administration.
There are three categories classifying drugs
for FDA review (diagnostic, vaccine, and
therapeutic) and each has a unique set of
requirements, regulations, and restrictions.
One of the key elements involved in the
expression of diagnostic factors from an
expression system is that the recombinant
protein must have biological activity com-
parable to the native protein, yet it must
not bind with proteins from the host cells
which would contribute to contamination
of the recombinant protein preparation.
Many insect cell factors, such as localiza-
tion and secretion signal peptides, or chap-
erone and folding proteins, do not recog-
nize the recombinant mammalian proteins.
Consequently, recombinant secreted mem-
brane and nuclear proteins remain in the
cytoplasm ofthe host cell. Thus, what was
a serious liability in the study of nuclear
and secreted proteins becomes one of the
strongest advantages in the production of
diagnostic proteins in BEVS. Auto-anti-
gens, cytochromes, G-protein coupled
receptors, and Herpes simplex virus capsid
proteins have successfully been produced
for diagnostic purposes in BEVS.
The development ofhuman and animal
vaccines is a second important BEVS med-
ical application. This emerging field was a
major focus ofdiscussion at the conference.
The first baculovirus-produced human vac-
cine, based on the immunodeficiency virus
(HIV-1) envelope glycoprotein gpI60,
began human clinical trials in 1987. Since
that time, immunogens produced in insect
cells from baculovirus vectors have been
tested as prophylactic vaccines against
acquired immunodeficiency syndrome
(AIDS), malaria, respiratory syncytial virus,
and influenza, and as therapeutic vaccines
for the treatment of AIDS and cancer.
Because these are new vaccines produced in
BEVS, not recombinant versions ofexisting
vaccines, a direct comparison to earlier
forms of the same vaccine is not available.
It is too early to determine whether the
The baculovirus expression vectorsystem(BEVS) and its applications.The gene ofinterest(red capsule)
is cloned intothe circular DNA ofthe baculovirus (top). The baculovirus infects Lepidopteran insectlarvae
or cultured insect cells. Viral replication occurs within the insect host cells, followed by expression ofthe
recombinant gene product (red protein ribbon structure). Potential uses of BEVS proteins are shown for
agriculture (lowerleft) as a biopesticide and in medicine (lowerright) as a vaccine ortherapeutic.
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subjects vaccinated with VaxSyn, the gpl60
AIDS vaccine, will remain free of the dis-
ease. However, current data from the
VaxSyn clincial trials reveal that after vacci-
nation, 100% of the uninfected subjects
and 80% ofthe HIV-infected subjects who
had a CD4 > 400 developed an epitope
antibody response. Approximately 50% of
all subjects (HIV negative and positive)
developed neutralizing antibodies. None of
the subjects displayed an allergic response
to the vaccine, although some did develop a
mild, local reaction. For veterinary medi-
cine, a baculovirus-produced vaccine for
bluetongue virus (BTV) successfully elicited
protective immunity in sheep when the
vaccinated sheep were challenged with the
homologous virulent bluetongue virus. The
global use ofvaccines is considered bysome
medical authorities to be the most cost-
effective strategy to prevent disease and
death. If the recombinant vaccines now in
clinical trials are successful, BEVS and
recombinant DNA technology offer the
future possibility of new and safer vaccines
for a number ofdiseases.
The class ofdrugs that faces the greatest
difficulty in receiving FDA approval is
human therapeutics. To date, no BEVS-
generated therapeutic drug has received
FDA approval to enter clinical trials, but
approval for one drug is imminent. A
recombinant membrane CD4 protein,
developed at the Center for Blood Research
Laboratories at Harvard Medical School, is
in final FDA review. The CD4 protein
functions as the high-affinity receptor for
the HIV envelope glycoprotein, gp 120.
The recombinant protein displayed the
same biological activityas the native human
CD4. The recombinant CD4 was elec-
troinserted in the membrane of red blood
cells (RBC-rmCD4) and then placed into
the lipid bilayer of liposomes. In vitro,
RBC-rmCD4 binds HIV particles, fuses
with the HIVenvelope, inhibits HIV infec-
tion of susceptible target cells and aggre-
gates HIV-infected cells. Another human
therapeutic in development reported at the
conference is a recombinant glucocerebrosi-
dase (GC), which is used in the treatment
ofGaucher's disease, a genetic lipid storage
disease. The proposal is to apply polyethyl-
ene glycol surface modification (PEGlation)
to the GC enzyme to enhance its use in
replacement therapy, improve circulation
half-life, and reduce immunogenicity.
Before these new drugs can be tested in
patients, they must be approved by the
FDA. Receiving FDA approval is an inten-
sive process in the development of human
therapeutics. The long and complicated
review is designed to screen all potential
new drugs and to safeguard the public
from remedies that have not been ade-
quately researched and tested. As a result,
many products do not reach clinical trial.
The complexity of the process and the
time and costs involved discourage some
companies from investing in expensive new
drug investigation research. As with all bio-
pharmaceuticals, the production laborato-
ries for BEVS products must meet strict
FDA standards for currrent Good Manu-
facturing Practices (cGMP), careful
Standard Operating Procedures (SOP)
must be developed and followed for every
procedure, and quality control procedures
for in-progress and final product testing
must be established for quality assurance
documentation. BEVS-synthesized phar-
maceuticals must meet additional require-
ments to ensure that an insect-synthesized
protein is biologically active and effective
against human disease and that there are
no insect contaminants that could compro-
mise patient safety. The master virus stock
for infecting insect host cells must be qual-
ified; the DNA sequence must be con-
firmed; and the high titer stock (HTS)
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must be free of mycoplasma, viruses, and
any other contaminants. The titer must be
confirmed by plaque assay. The insect host
cells must be screened and rigorously
maintained in a Working Cell Bank and a
Master Cell Bank. The recombinant pro-
tein must be highly purified, and all traces
of the insect host cells and baculovirus
removed. All tissue culture procedures
must be highly reproducible. Recombinant
technology has often received negative
reviews from the media and generated safe-
ty concerns from the public, which must
be addressed once FDA approval is
obtained. The acceptance and success of
CD4 and GC will pave the way for a
bounty ofrecombinant biopharmaceuticals
in this new technology frontier.
Scale-Up Technology
Commercial BEVS applications in medi-
cine and agriculture will require large
quantities of the recombinant protein and
thus continued advances in bioengineering
for large-scale production; several facets of
this technology were presented at the con-
ference. Increasing the volume and mass of
a suspension culture is not a linear process,
and it presents many logistical problems.
Scale-up from conventional 100-mL sus-
pension culture to 36-L stirred reaction
vessels and 100-L bioreactors has been suc-
cessfully accomplished, with no change in
the kinetics ofcell growth and protein pro-
duction. The key to successful scale-up in
any mechanical system is the harmonious
optimization ofall components ofthe sys-
tem. Because insect cells experience a 30%
increase in oxygen uptake immediately
P Mis insect cell as a eukatyotic gene expression sys-
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after infection, it is usually necessary to
agitate the system or to perfuse or inject
oxygen into the reaction vessel to prevent
anoxia and changes in pH level of the
medium. Replacement of growth-limiting
nutrients via hollow-fiber microfiltration
or a programmed feeding strategy is nece-
sary for efficient metabolism and to pre-
vent excessive by-product accumulation.
The multiplicity ofinfection (MOI) ofthe
high titer stock and the MOI ratios in
multiple infections are important kinetic
factors, which generated a great deal ofdis-
cussion among conference participants.
Infecting at a low MOI (0.1-0.2) is eco-
nomical, but allows one population dou-
bling before the cells engulfthe virus. This
can improve cell health, but it can also
cause an asynchronous culture. New
advances in bioreactors include a NASA-
developed, reduced shear, low turbulence
microgravity (0.2 dyne/cm2) vessel, the
high-aspect ratio vessel (HARV), and a
dielectrophoresis system (DEP), which
uses a nonuniform electric field to remove
nonproductive, dead cells from the reactor.
Summary
The BEVS continues to evolve as a power-
ful, flexible tool for molecular biology,
protein function, and biomedical research.
Future developments offer the promise of
replacement ofhazardous chemical insecti-
cides with environmentally safe biopesti-
cides, construction of baculovirus vectors
which encode genes for specific post-trans-
lational modifications, and establishment
of efficient, stably transformed insect cell
lines. FDA approval of BEVS-produced
products offer the prospect of new bio-
pharmaceuticals, in particular human ther-
apeutics and vaccines, to improve human
health and increase the quality of life for
millions ofpeople.
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